Amgen Inc. (AMGN) is mainly concerned with inflammation, oncology, bone health, cardiovascular disease, nephrology, and neurology. It has a collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for treating atopic dermatitis and other autoimmune diseases, as well as a research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc.
The company’s shares have gained 10.5% over the past year and 5.6% over the past month to close its last trading session at $248.69. It has over 50 ongoing programs in its pipeline, and the business is more than capable of providing additional approvals or label extensions.
